Home>>NP213 TFA

NP213 TFA

Catalog No.GC60271

NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities.

Products are for research use only. Not for human use. We do not sell to patients.

NP213 TFA Chemical Structure

Size Price Stock Qty
5mg
$250.00
In stock
10mg
$399.00
In stock
25mg
$705.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections[1][2].

NP213 (500-1000 μg/mL; 18 hours) increases the number of PI-stained T. rubrum NCPF0118 cells in samples. This results suggests that NP213 is fungicidal and the mechanisms of action involved membrane permeabilization[1].NP213 is against T. rubrum NCPF0118, shows different MIC values against T. rubrum NCPF0118, and the MICs varies depending on the source of the keratin. The MIC values are 16-32 mg/L, 125 mg/L, and 250 mg/L for NP213 in 1640 media containing human nail Keratin, human skin Keratin and Lamb's wool Keratin, respectively[1].NP213 TFA (2-3 hours; 0-8 μg/ml) has great activity against clinically relevant yeast, including candida spp, Cryptococcus spp and Trichosporon spp. For all 122 yeast isolates, with the median MIC100 values of 1-2 µg/ml[3]. Cell Cytotoxicity Assay[3] Cell Line: Clinically relevant yeast isolates

NP213 TFA (25 mg/kg) is well tolerated in mice. In Murine models of acute disseminated candidiasis, NP213 is tolerated and efficacious and exhibits a half-life of approximately 4.5 h[3].

[1]. Mercer DK,et al. Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate.Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02117-18. [2]. Neelabh, et al. Sequential and Structural Aspects of Antifungal Peptides from Animals, Bacteria and Fungi Based on Bioinformatics Tools.Probiotics Antimicrob Proteins. 2016 Jun;8(2):85-101. [3]. Novamycin®/NP339 Technology Summary

Reviews

Review for NP213 TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NP213 TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.